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Role of Nutrient and Energy 





Cell survival depends on the constant challenge to match energy demands with 
nutrient availability. This process is mediated through a highly conserved network 
of metabolic fuel sensors that orchestrate both a cellular and whole-body energy 
balance. A mismatch between cellular energy demand and nutrient availability is a 
key factor in the development of type 2 diabetes, obesity, metabolic syndrome, and 
other associated pathologies; thus, understanding the fundamental mechanisms by 
which cells detect nutrient availability and energy demand may lead to the develop-
ment of new treatments. This chapter reviews the role of the sensor PASK (protein 
kinase with PAS domain), analyzing its role in the mechanisms of adaptation to 
nutrient availability and the metabolic response in different organs (liver, hypothal-
amus) actively cooperating to control food intake, maintain glycaemia homeostasis, 
and prevent insulin resistance and weight gain.
Keywords: PASK, mTOR, AMPK, obesity, food intake, fasting/feeding, GLP-1
1. Introduction
Nutrients such as carbohydrates, amino acids, fats, vitamins, minerals, etc. 
are supplied at regular intervals by food intake and are necessary for the normal 
functioning of cells and a healthy physiology [1]. They act as metabolic substrates 
for energy production and as building blocks for the synthesis of macromolecules 
and cellular components. Accordingly, organisms have developed mechanisms to 
detect levels of specific nutrients in the extra- and intracellular compartments to 
ensure rates of growth, proliferation, and function coordinate properly and adjust 
to nutrient availability.
2.  Nutrients and energy sensors: importance in glucose and energy 
homeostasis
Nutrient-sensing mechanisms are found in all organisms, from yeast through to 
mammals. Importantly, some of these mechanisms in multicellular organisms have 
also evolved for regulation by the endocrine system, allowing the coordination of 
nutrient-sensing activity among different cells/tissues in the body [2].
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Nutrient sensors are proteins that detect fluctuations in nutrient levels or 
products of their metabolism within the physiological range, and induce a cellular 
response, leading to changes in the nutrient distribution or in feeding behavior [1]. 
These sensors respond to alterations in nutrient levels through diverse mechanisms, 
including the activation of phosphorylation cascades, changes in gene transcription, 
and enzymatic activities, among others [2].
The sensing of a nutrient may involve the direct binding of its molecule to the 
sensor or an indirect mechanism relying on the detection of a surrogate molecule 
that reflects nutrient abundance. There are homeostatic responses in multicellular 
eukaryotes to maintain nutrient levels circulating within a narrow range, such as 
hormone release, which act as signals to facilitate the coordination of consistent 
responses in the whole organism [3].
An effective and adequate response to changes in nutrient availability is vital in 
the human body, and its alteration triggers pathologies such as obesity, metabolic 
syndrome, and aging-related diseases (e.g. cancer and neurodegeneration).
Some situations in which nutrient sensors are chronically affected by excessive 
amounts of certain nutrients (e.g. carbohydrates and some fats) lead to the develop-
ment of common characteristics of obesity and type 2 diabetes mellitus (T2D), such 
as insulin resistance, oxidative stress, and the dysfunction of organelles including 
the endoplasmic reticulum and mitochondria [4].
The increasing number of overweight and obese people, and associated diseases 
such as T2D, is driving research to explore the basic mechanisms that maintain 
nutrient homeostasis in a healthy state and the molecular mechanisms disrupted 
in T2D and obesity, as well as the neural and molecular underpinnings of feeding 
behavior. A central role in these disease-related mechanisms corresponds to nutrient 
sensing and the regulation of feeding behavior [1].
Glucose is a critical nutrient in mammals, with extracellular and intracellular 
mechanisms to maintain its levels within a narrow physiological band.
Glucose is an energy substrate, but it is also a key molecule in the control of glucose-
dependent insulin secretion by the pancreas. The increase in insulin in the blood as 
glycaemia facilitates the uptake of glucose by the liver and skeletal muscle, highlighting 
the cooperation and retro-regulation between glucose and insulin signaling. In short, 
circulating and intracellular glucose, acting as a signaling molecule, is detected by 
different glucose sensors that modulate eating behavior and the release of counter-
regulatory hormones in response to hypoglycemic states. The answer is therefore to 
maintain glucose and energy homeostasis [5], avoiding the development of T2D and 
other diseases. Some of the main nutrient sensors described are the following:
• Glucokinase (GCK): It is an enzyme that catalyzes the phosphorylation of 
glucose to glucose-6-phosphate. GCK is expressed in hepatocytes, pancreatic 
α and β cells, entero-endocrine cells, and specialized brain cells in humans and 
most other vertebrates. It is considered a true glucose sensor due to its kinetic 
properties that ensure that the rate of glucose phosphorylation is proportional 
to blood glucose levels. For example, pancreatic GCK connects glucose sensing 
to insulin secretion by the pancreatic β-cell, and so regulates blood glucose 
homeostasis.
GCK in the liver is also a glucose sensor (Figure 1). Its activity regulates the 
rate of glycogen accumulation and hepatic glucose production [6].
Mutations in the GCK gene that increase enzyme activity lead to hypoglycemia 
due to hyperinsulinism, while mutations that decrease enzyme activity lead to 
hyperglycemia or diabetes. Due to its importance in glucose homeostasis, this 
enzyme is one of the main study targets for the development of a new antidia-
betic therapy strategy [7].
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Additionally, GCK is a key component in glucose-sensing neurons located in 
the hypothalamus [8–10].
• Glucose transporter GLUT-2: It is a glucose transporter that acts as a sensor 
of changes in extracellular glucose levels. This is due to a high Km (more than 
other glucose transporters of the same family) and thus a very low affinity 
for glucose, allowing a rapid equilibrium between the glucose concentration 
on both sides of the membrane, independently of the action of insulin [11]. 
GLUT2 is expressed mainly in hepatic cells, pancreatic β cells, basolateral 
membranes of intestinal, renal epithelial cells, and in specific brain nuclei. 
In hepatic cells, GLUT2 involves an efficient transport of glucose across the 
plasmatic membrane only when intra- or extra-cellular glucose is high, being 
a key controller of glucose homeostasis (Figure 1). β-pancreatic cells take up 
glucose through the GLUT-2 transporter and carry out insulin synthesis and 
secretion. Glucose transport by GLUT-2 and then GCK facilitates oxidation by 
increasing intracellular ATP, which leads to signaling via ATP-dependent K+ 
channels [1]. Decreased GLUT2 levels in pancreatic β cells have been detected 
in cases of diabetes in both animals and human patients.
GLUT2 is also found in neurons located in certain glucose-sensing brain 
regions involved in controlling feeding behavior [9, 12, 13].
• AMP activated protein kinase (AMPK): It is a heterotrimeric complex 
with a serine/threonine kinase domain [14, 15]. AMPK perceives cellular 
energy availability by detecting the AMP/ATP ratio (Figure 1). This kinase is 
activated in states of low energy availability or metabolic stress that reduces 
Figure 1. 
PASK signaling interaction with other nutrient sensors. PAS domains detect environmental parameters (light, 
oxygen and redox state). A metabolite or protein binds to the PAS domain after transient activation auto- or 
transphosphorylation stabilizes and activates PASK. Physiological effects of PASK in other nutrient sensors 
(glucose transporter (GLUT2), glucokinase (GCK), AMP-activated kinase (AMPK) and mammalian target 
of rapamycin (mTOR))/S6K pathway due to activation or inhibition (direct: solid lines; indirect: dashed 
lines).
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ATP production (e.g. heat shock, hypoxia, ischemia and fasting conditions) 
or accelerates its consumption (muscle contraction). Once active, AMPK acts 
by inhibiting the anabolic pathways responsible for the synthesis of macro-
molecules (proteins and glycogen) and lipids (fatty acids, triglycerides and 
cholesterol), and by activating catabolic pathways, such as the β-oxidation 
of fatty acids, glucose uptake and glycolysis. The net result of AMPK activity 
is the restoration of the energy balance, as the main energy sensor [16]. The 
AMPK pathway at central level integrates peripheral information through 
nutrients and hormones. Hypothalamic AMPK is involved in feeding behavior, 
the thermogenesis of brown adipose tissue (BAT) and browning of white 
adipose tissue (WAT) [17, 18].
• Mammalian Target of Rapamycin (mTOR): The mTORC1 complex is a 
serine/threonine kinase which forms part of the mTOR/S6K pathway inte-
grating nutrients, hormones, growth factors and cellular energy levels to 
control protein transcription and synthesis and cell size, growth, metabolism, 
autophagy and thermogenesis [19]. Growth factors, amino acids, mitogens, 
and favorable energy states activate the mTORC1/S6K1 pathway, promoting 
anabolic processes (Figure 1), while states of energy depletion and cellular 
stress such as hypoxia suppress this pathway. The hypothalamic mTORC1 
complex is an energy sensor involved in food intake and body weight control 
[20, 21]. AMPK and mTORC1 act together in food intake regulation, as low 
nutrient levels during fasting activate AMPK, although the mTORC1 complex 
remains inactive, while the activity of these sensors is reversed after food 
ingestion, indicating that AMPK and mTORC1 could have opposite functions 
in the control of feeding behavior [22].
• PAS kinase (PASK): It is also called PASKIN, and is defined as the protein 
kinase that contains an N-terminal Per-Arnt-Sim (PAS) domain and a 
C-terminal serine/threonine kinase catalytic domain [23]. Like AMPK and 
mTORC1, it is a nutrient-responsive protein that regulates glucose metabolism 
and cellular energy, and is also responsive to a variety of intracellular cues, 
including light, oxygen, and redox state, among many others [24]. In mam-
mals, PASK may be activated by small metabolites, and could regulate glycogen 
synthesis and protein translation (Figure 1), in addition to being involved in 
the regulation of glucose homeostasis and energy metabolism [25–27], and 
epigenetics and differentiation [28].
This chapter will focus on the study of this last sensor, and like AMPK and 
mTORC1, it can be considered a pharmacological target for diseases, such as obesity 
and diabetes.
2.1 Neuronal and peripheral regulation of homeostasis by nutrient sensing
The key to maintaining homeostatic and energy control is a balanced food 
intake and energy expenditure, whereas altered regulation leads to obesity and 
T2D. The regulation of the energy balance is controlled by the hypothalamus, as 
the central organ that integrates nutrient levels and hormonal changes. The hypo-
thalamic response to regulate glucose and whole-body energy homeostasis is to 
control food intake and several physiological functions in peripheral organs, such 
as lipid metabolism and thermogenesis [29, 30]. The brain receives inputs from 
nutrients, adiposity signals, and hormonal neural and metabolic signaling from the 
gastrointestinal tract. The gut-brain and gut-brain-liver axes act to regulate energy 
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and glucose homeostasis, respectively [31–33]. The brain likewise controls energy-
consuming processes such as skeletal muscle fatty acid oxidation, thermogenesis, 
and locomotor activity [34]. Deficient intercommunications between the brain and 
peripheral organs may contribute to the appearance of obesity and T2D [30, 33].
The hypothalamus is a key brain area for maintaining an energy balance and 
homeostasis. Hypothalamic areas thereby play a key role in the control of food 
intake and energy homeostasis. The mid-20th century recorded the first indications 
that the electrical stimulation of the ventromedial hypothalamus (VMH) sup-
presses food intake, and that bilateral lesions of these areas induce hyperphagia and 
obesity. The VMH has therefore been called the satiety center. By contrast, altera-
tions in the lateral hypothalamic area (LH) induce the opposite set of responses, 
and the LH is hence called the hunger center. Changes in blood glucose levels can 
be monitored by neuronal cells located in the hypothalamus or the brain stem [35]. 
They can therefore act as a true glucose sensor in the control of food intake and 
energy homeostasis. In fact, the first brain glucose sensors were discovered in the 
VMH and LH nucleus, where circulating glucose concentrations drive changes in 
neuronal electrical activity [36, 37]. This means glucose would act mainly as an 
excitatory molecule in certain VMH neurons, and as an inhibitory molecule in those 
of LH and the nucleus of the tractus solitarius (NTS) [38]. This is due to at least two 
kinds of glucose sensor neurons: glucose-excited neurons (GE) are located mainly 
in the VMH (as well as the arcuate nucleus, ARC, and the paraventricular nucleus 
PVN), and are excited by increased glucose levels in the extracellular space, while 
glucose-inhibited neurons (GI) are present mainly in the LH, median ARC, and 
PVN, and are excited by decreases in glucose concentrations [10, 37, 39]. It has been 
suggested that the activation of the firing rate of GE neurons depends on the closure 
of the ATP-sensitive K+ATP channels by increases in extracellular glucose (similar 
electrophysiological pattern to β-pancreatic cells), whereas GI neurons may increase 
their firing rate in response to hypoglycemia following the inactivation of the Na+/
K+-ATPase pump (similar electrophysiological pattern to α-pancreatic cells) [40].
Some of the component molecules responsible for the hypothalamic glucose 
sensing systems are as follows: GCK, GLUT-2, and the GLP-1 receptor, which are 
co-expressed in areas involved in energy homeostasis regulation, food intake, and 
glucose metabolism [9, 12, 41, 42]. The most glucose-sensitive regulator seems to be 
the GCK, which is present in both GE and GI neurons (albeit to a lesser extent) [43]. 
However, glucose transporters such as GLUT-2, GLUT-3, the insulin-dependent 
transporter (GLUT-4), and the sodium-glucose transporter (SGLT) do not seem 
to have a predominant role in the response by GE and GI neurons to alterations in 
glucose levels [10]. GE neurons are known to use GLUT-2 for glucose uptake, then 
GCK mediates the phosphorylation, and the glucose oxidation increases ATP/ADP, 
leading to the closure of ATP-sensitive K+ATP channels and depolarization, promot-
ing Ca2+ influx and neurotransmitter release [33, 44, 45].
Hypothalamic sensing neurons also use fatty acids (FA) as signaling molecules 
[46]. Some of these sensing neurons respond to both FA and glucose, whereby these 
neurons distinguish between fasting and feeding states. When the effect of glucose 
is excitatory, FA tend to inhibit those neurons [46]. A deficiency of fatty acid trans-
locator/receptor CD36 in VMH neurons stimulates food intake, enhances insulin 
resistance, and increases body weight and fat mass in lean and obese rats [47]. FA 
sensing therefore plays a key role in integrating signals for regulating glucose and 
energy homeostasis and fat deposition.
It has also been reported that FA are oxidized by astrocytes in VMH under a 
low-fat diet, while under a high-fat diet (HFD) astrocytes in this area generate 
ketone bodies that can be exported to neurons and signal a decrease in short-term 
food intake and protect against obesity. However, this effect is lost when besides 
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HFD there is a resistance to leptin. Animals in these cases remain hyperphagic and 
exposed to obesity [48].
Additionally, with changes in nutrient concentrations some neurons located 
in hypothalamic nuclei secrete and respond to the hormones and neuropeptides 
involved in the control of food intake and energy homeostasis.
For example, the ARC secretes hormones and detects inputs from the periph-
eral signals involved in the control of feeding behavior. There are two important 
subpopulations of secretory neurons in ARC: one synthetizes the α-melanocyte-
stimulating hormone (α-MSH) derived from pro-opiomelanocortin (POMC), 
as well as the cocaine- and amphetamine-regulated transcript (CART); both of 
which are anorexigenic peptides. The second subpopulation of neurons secretes 
the agouti-related protein (AgRP) and neuropeptide Y (NPY) orexigenic peptides 
[49]. These peptides are directed by nerve fibers to other important hypothalamic 
regions, and their synthesis and release coordinate with metabolic sensors to 
accurately control eating behavior and energy metabolism. Additionally, these two 
populations and other neurons located in different hypothalamic nuclei have recep-
tors for hormones secreted peripherally, such as leptin, insulin, ghrelin, and other 
gastrointestinal peptides, such as glucagon like peptide (GLP-1), which in turn are 
being secreted under the control of changes in nutrient availability.
AMPK is another hypothalamic molecule responsible for energy sensing. It has 
been reported to act as an “energy integrator”, and not only perceives the cellular 
energy state, but also has a role in the regulatory mechanisms of body energy 
homeostasis [50, 51]. It has a mainly neuronal distribution [52], highly expressed in 
ARC, PVN, VMH and LH, with AMPKα2 being the most predominant isoform [53].
Fasting increases and feeding decreases AMPK activity in various hypothalamic 
nuclei [18, 53]. Several studies have shown that hypothalamic AMPK is regulated by 
blood glucose levels. Peripheral or central hyperglycemia inhibits AMPK in several 
hypothalamic nuclei. Furthermore, the anorexigenic neuronal signaling (NPY/
AgRP) is AMPK-dependent in the hypothalamus. Thus, AMPK mutants have sup-
pressed the NPY/AgRP response, and therefore food intake, reducing body weight. 
However, elevated AMPK increases NPY/AgRP expression, food intake and body 
weight [53, 54].
Fasting and feeding are accompanied by hormonal and nutrient changes both 
in peripheral tissues and in the CNS, which can lead to variations in AMPK activ-
ity. Accordingly, AMPK integrates nutritional information and hormonal signals. 
Several studies have shown that fasting and orexigenic signals (e.g. ghrelin, 
 adiponectin, cannabinoids and glucocorticoids) increase hypothalamic AMPK 
activity, contributing to an increase in food intake; by contrast, food and anorectic 
signals such as leptin, insulin, resistin, GLP-1 and α-MSH decrease this kinase’s 
activity, helping to generate a state of satiety. AMPK activation therefore promotes 
food intake, while the decrease in its enzymatic activity is associated with hypopha-
gia. This effect is due, at least in part, to an increase in the expression of NPY and 
AgRP in the arcuate nucleus, and of MCH in the lateral hypothalamus [17, 18, 54].
AMPK activity can induce appetite via the inhibition of malonyl-CoA and 
the activation of carnitine palmitoyltransferase-1 (CPT-1). The inhibition of 
malonyl-CoA leads to decreased fatty acid synthesis and increased 𝛽-oxidation. 
Furthermore, increased 𝛽-oxidation could induce orexigenic gene expression. In 
addition, AMPK activation through the sympathetic nerve can reduce thermogen-
esis and energy expenditure. Additionally, activated hypothalamic AMPK may 
prompt enhanced glucose production [55].
Besides AMPK, mTORC1 is another hypothalamic metabolic sensor regulator of 
feeding behavior and body weight [20]. mTORC1 and the downstream target S6K1 
are widely distributed in the brain, mainly in the PVN and ARC. Their signaling 
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responds to nutrient availability and is colocalized with NPY/AgRP and POMC/
CART neurons in the ARC [20]. mTORC1 activation decreases food intake and body 
weight [56]. mTORC1 integrates signals from nutrients, adiposity signals, and gut 
hormones [21]. Hypothalamic AMPK and mTORC1 respond to nutrient levels in 
opposite ways [57, 58]. Additionally, mTORC1 is inhibited by AMPK activation via 
the tuberous sclerosis complex 2 (TSC2) [59, 60]. Moreover, AMPK is also a substrate 
for the mTOR-S6K1 pathway (Figure 1) [22].
In short, the interplay between both hypothalamic pathways plays an important 
role in regulating food intake and body weight.
Several peripheral signals are involved in controlling food intake and energy 
homeostasis. Moreover, changes in nutrient levels involving glucose [61] and FA 
[62, 63] or ketone bodies [48], adiposity signals (leptin, insulin) [64], and gas-
trointestinal (ghrelin [65], GLP-1 [57, 58, 66]) signals, alter the activity of sensing 
neurons located in the VMH and other brain areas.
Two peripheral hormones, leptin and insulin, provide the brain with informa-
tion about the energy stored as adipose tissue [64]. Leptin and insulin levels in 
plasma correlate with adipose mass and body weight. Insulin levels correlate better 
with visceral adiposity [67]. Its plasma levels also reflect changes, decreasing during 
fasting and increasing during feeding; glucose-induced insulin secretion is also 
dependent on body fat (review by Benoit et al.) [64]. Obesity is frequently related 
to insulin resistance as higher insulin levels are required to maintain suitable levels 
of blood glucose. The administration of insulin to the brain reduces food intake and 
increases energy expenditure [68]. Impaired insulin signaling due to neuronal dele-
tion of the insulin receptor and insulin receptor substrate 2 (IRS2) increases food 
intake [69]. Leptin is secreted by adipose tissue, and blood levels correlate directly 
with adiposity [70]. Leptin receptor deficiency has been related to hyperphagia and 
obesity [71]. However, leptin supplied to the ARC reduces food intake and body 
weight, and promotes locomotor activity [72].
Hormones secreted in the gut after feeding as cholecystokinin and GLP-1 
promote satiety when administered centrally and peripherally [66]. By contrast, 
ghrelin released under fasting conditions by the stomach acts as an orexigenic signal 
inducing food intake [31].
The liver plays a vital role in regulating whole-body glucose and lipid homeo-
stasis. It is the main site for the synthesis, metabolism, storage and redistribution 
of carbohydrates, proteins and lipids, especially during the adjustment periods in 
fasting and feeding. In postprandial states, the liver is exposed to more ingested 
nutrients and to higher levels than other tissues. The liver is especially responsible for 
much of glucose uptake when hyperinsulinemia and hyperglycemia coincide, storing 
it as a glycogen and associated to a reduction in muscle glucose uptake [73]. The 
efficiency of hepatic glucose uptake is coordinated neurally, depending also on diet 
components and high-fat and high-fructose decreases in glycogen storage. Glucose 
transport is facilitated by GLUT2, with the intrahepatic glucose concentration being 
similar to that of blood glucose. Its metabolism therefore depends on GCK activity, 
which in part determines glycogen synthesis [74]. By contrast, when blood glucose 
drops, and other organs require energy, the liver produces glucose by glycogenolysis 
and/or gluconeogenesis. Gluconeogenesis is responsible for half of the total glucose 
produced by the liver during an overnight fast, so this contribution is essential for 
glucose homeostasis [75]. Therefore, hepatic metabolism is critical for proper glucose 
homeostasis in response to insulin and for preventing diabetes [73, 75]. Insulin in the 
hypothalamic nuclei regulates hepatic glucose production [76, 77]. Insulin acts on 
the brain (hypothalamus and brain stem), also modulating pancreatic insulin and 
glucagon secretion [78]. The close coordination between the brain and peripheral 
organs helps to maintain whole-body glucose and energy homeostasis.
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In turn, there is a close relationship between the appearance of insulin resis-
tance in the liver and the development of T2D [79, 80]. Decreased hepatic insulin 
sensitivity contributes to postprandial hyperglycemia and enhances hepatic glucose 
production, leading to exacerbated hyperglycemia and chronic hyperinsulinemia 
in diabetics [81]. There is evidence to suggest that impairing insulin hypothalamic 
signaling [82] or an HFD [83] contributes to the appearance of diabetes.
3. PASK: a new nutrient sensor
PASK is an evolutionarily conserved nutrient-responsive protein kinase that 
regulates glucose homeostasis, senses a cell’s energy or nutrient status, and suitably 
regulates cellular metabolism. PASK responds to glucose availability and regulates 
glucose homeostasis in yeast, rodents and mammals. Despite this pivotal role, the 
molecular mechanisms of PASK regulation and function are largely unknown [84].
PAS domains (see Section 2) are versatile sensors designed to detect environ-
mental parameters, such as light, oxygen and redox state [24]. These domains are 
often regulated by the binding of a diverse group of small ligands, including ATP, 
heme or flavins, within the hydrophobic pocket at the core of the domain (review 
by Henry et al.) [85]. As with other PAS domains, the PASK adopts this charac-
teristic fold and binds small organic molecules within its hydrophobic core [86]. 
Unlike other PAS domains, however, the physiological ligand(s) for PASK remain 
unknown. In vitro experiments performed indicate that this domain should inhibit 
kinase activity [84].
In a hypothetical activation model, a metabolite or protein activates PASK by bind-
ing to the PAS domain and relieving PAS domain inhibition. This transient activation 
may subsequently be stabilized through auto- or transphosphorylation (Figure 1). 
PASK can then phosphorylate several substrates (Figure 2) [23, 27, 86, 87].
PASK is known to be a physiological regulator of glucose metabolism, function-
ing in pancreatic islet cells regulating glucagon and insulin secretion [88, 89]; 
several translation factors and glycogen synthase are PASK substrates [90, 91], sug-
gesting its implication in the control of protein synthesis and glycogen metabolism.
Figure 2. 
PAS Kinase substrates in mammals. Cellular process regulated by PAS kinase and in vitro or in vivo substrates 
identified in mammals. Glycogen metabolism: Glycogen synthase (GYS), Glycogen synthase kinase 3 beta 
(GSK3β). Protein translation: Alanine-tRNA ligase (AlaRS); Basic transcription factor 3 (BTF3); Eukaryotic 
translation elongation factor (eIF1A); Ribosomal proteins S2, S3A, S6, S8, S10 and S14 (RPS2), (RPS3A), 
(RPS6), (RPS8), (RPS10) and (RPS14). Gene expression: Histone H3 tails residues threonine 3, 6, 11 and 
serine 10 (H3T3), (H3T6), (H3T11) and (H3S10); Cell differentiation: WD repeat-containing protein 5 
(WDR5) and Pancreatic Duodenal Homeobox 1 (PDX1).
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Katschinski et al. [92] have been the first to inactivate mouse gene coding to 
PASK. These PASK-deficient mice (PASK−/−) recorded normal development, growth 
and reproduction. It was subsequently found that PASK−/− male mice are resistant to 
weight gain, hepatic triglyceride accumulation, and insulin resistance when placed 
on an HFD [93]. Without a change in food intake or exercise, these PASK−/− male 
mice also record a hypermetabolic phenotype, giving off more CO2 and taking 
in more O2. PASK is involved in the proteolytic maturation of the sterol regula-
tory binding protein (SREBP1c), the main lipogenic transcription factor [94, 95]. 
SREBP1c activity and target genes decreased in PASK−/− mice, with an associated 
decrease in hepatic lipid deposits [96].
Lipids are important substances that store energy for oxidation and metabolism. 
As the main cause of imbalanced lipid metabolism, excessive lipid accumulation 
in the liver has been involved in the development of metabolic syndromes, such as 
T2D, obesity, hepatic adipose infiltration and unpredicted morbidity. It is therefore 
extremely important to maintain a balance between lipid synthesis and catabolism. 
PASK has been reported to regulate many of the phenotypes.
PASK deficiency decreases insulin production, insulin resistance, body weight 
and hepatic triglyceride accumulation, while leading to increased glycogen storage, 
as well as metabolic rate [97]. Some of the effects observed in PASK−/− have also 
been confirmed using PASK pharmacologic inhibitors [98].
Our studies have been based on this mouse model. PASK−/− mice have been 
described by Hao et al. [93], and generously donated to us by Dr. Roland H. Wegner 
(Veterinary Department of the canton of Zurich).
New PASK functions have recently been described, including the unexpected 
role it has in promoting the differentiation of myogenic progenitor cells, embryonic 
stem cells, and adipogenic progenitor cells. This PASK function is dependent upon 
its ability to phosphorylate WD repeat-containing protein 5 (WDR5), which is a 
member of several protein complexes, including those that catalyze histone H3 
Lysine 4 trimethylation (H3K4me3) during transcriptional activation. Thus, as an 
upstream kinase of WDR5, PASK integrates signaling cues with the transcriptional 
network to regulate the differentiation of progenitor cells [99]. In addition, the 
phosphorylation of PASK by mTORC1 is required for the activation of myogenin 
transcription, exiting from self-renewal, and the induction of the myogenesis 
program. mTORC1-PASK signaling is required for increasing myogenin-positive 
committed myoblasts (early stage of myogenesis) [100].
Moreover, it has been confirmed that the metabolic sensor PASK could affect 
both the phosphorylation and the methylation of histone H3 tails. It contributes to 
the methylation of H3 lysine 4 (H3K4) di- and tri-methylation through its associa-
tion with the H3K4 MLL2 methyltransferase complex and to the phosphorylation 
of several threonine residues (T3, T6 and T11) and serine (S10) on H3 as a histone 
kinase [101]. The methylation of histone H3 lysine 4 H3K4 has been linked to 
transcriptional activation.
4. PASK hypothalamic function in food intake and energy homeostasis
The hypothalamus is the key to controlling food intake. The identification of 
hypothalamic glucose sensing systems and neuronal populations expressing and 
responding to orexigenic and anorexigenic peptides (see Section 2.1) has focused 
the studies on the hypothalamic nuclei. They have been specifically directed toward 
identifying the mechanisms involved in controlling nutrient sensing, feeding 
behavior and its relationship with insulin actions in the central nervous system in 
order to regulate energy and glucose homeostasis. Hypothalamic metabolic sensors 
Type 2 Diabetes - From Pathophysiology to Cyber Systems
10
respond in opposite ways to changes in nutrients and orexigenic or anorexigenic 
peptides, and their activation/inhibition regulates food intake. For example, the 
hypothalamic AMPK is activated by fasting and inhibited by refeeding [53, 57, 102], 
and the mTORC1/S6K pathway is activated by glucose and amino acids, inhibiting 
food intake [20, 57, 103]. Both pathways are involved in controlling feeding and 
regulating the energy balance.
In 2013, PASK was identified in the hypothalamic areas involved in feeding 
behavior, and its expression was regulated under fasting/refeeding conditions  
[104, 105]. It was proposed as a hypothalamic and liver nutrient sensor and a general 
regulator of glucose metabolism and cellular energy. Moreover, PASK−/− mice resist 
diet-induced obesity [93]; it might therefore be understood that PASK could control 
the hypothalamic function related to intake control. For example, elevated glucose 
levels decrease mRNA coding to PASK in VMH and LH areas in hypothalamic 
organotypic cultures and in neuroblastoma N2A cells [104]. The PASK expression 
is also regulated in vivo in response to fasting/refeeding conditions. This effect is 
clearer in LH: mRNA coding to PASK is lower under fasting conditions and increases 
in response to refeeding conditions [105]. The effect observed after refeeding in vivo 
is the opposite to the glucose effect found in VMH and LH in hypothalamic organo-
typic cultures and neuroblastoma N2A cells. However, the effect is similar to those 
produced in the presence of both glucose and the anorexigenic peptide GLP-1 (an 
incretin release from intestinal L-cells in response to feeding) [106, 107]. The role of 
PASK in the hypothalamus would be similar to other well-known metabolic sensors, 
such as AMPK and mTORC1. The activation of AMPK and mTORC1 is coordinated 
and antagonistic. While AMPK is activated by a fall in energy, mTORC1 is activated 
by its increase. Hypothalamic metabolic sensors, such as AMPK and mTORC1, 
therefore play an important role in feeding behavior, body weight homeostasis, 
and energy balance (see Section 2.1). These sensors respond to changes in nutrient 
levels in the VMH and LH (hypothalamic areas involved in feeding behavior) and in 
neuroblastoma N2A cells, and those effects are modulated by the GLP-1 in lean and 
obese rats [57].
Studies in PASK−/− mice have indicated that PASK-deficiency involves a down-
regulation of mRNA levels coding to AMPKα2 in VMH, and slightly so in LH [105], 
while impairing the coordination of the AMPK and mTORC1/S6K1 pathways. Thus, 
both the AMPK and mTORC1/S6K1 pathways are surprisingly activated at the same 
time under fasting and feeding conditions in PASK−/− mice [105]. This finding could 
mean that the inhibition of mTORC1/S6K through AMPK activation requires the 
coordinated phosphorylation of TSC2 by Glycogen synthase kinase 3β (GSK3β) 
[59], which is a PASK substrate in vitro, and PASK deficiency could therefore alter 
hypothalamic GSK3β activity [108]. Additionally, this study has found that the 
exendin-4 regulatory effect on metabolic sensor activity is lost in PASK−/− mice, 
and the anorexigenic properties of exendin-4 significantly reduced, suggesting that 
PASK could be a mediator in the brain GLP-1 signaling pathway. Some of the anti-
diabetogenic effects of exendin-4 might be modulated through these processes. This 
means that hypothalamic PASK, interacting with AMPK and mTORC1 pathways, 
and in coordination with anorexigenic/orexigenic peptides, could be a key enzyme 
in food intake control, and in peripheral tissue functions, such as brown adipose 
tissue thermogenesis, pancreatic insulin secretion, etc. However, more studies are 
needed to clarify this hypothesis and the putative molecular mechanism of PASK 
actions in whole-body physiology.
The downregulation of mRNA coding to AMPKα2 and the modulation of the 
GLP-1 effects in hypothalamus in PASK−/− mice suggest that both effects may also be 
regulating thermogenesis in BAT and the browning of white fat, as both processes 
are mediated by the inhibition of hypothalamic AMPK [109, 110].
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As well as acting in hypothalamic functions, PASK also has key functions in the 
peripheral tissues. For example, diabetes and PASK have been linked, as a human 
mutation of the PASK gene has been correlated with maturity-onset diabetes of the 
young (MODY). This mutation increases kinase activity and decreases glucose-
stimulated insulin secretion by the pancreas [111]. In addition, decreased PASK 
expression in pancreatic islets has been reported in human T2D [88]. The PASK 
function in peripheral tissues could be crucial for maintaining metabolic and 
energy homeostasis.
5. PASK contribution to hepatic adaptation to fasting/feeding
The liver maintains metabolic homeostasis, and it is especially essential in the 
proper control of glucose during fasting and feeding periods. In particular, the liver 
is one of the main insulin-responsive organs, so it records a greater glucose uptake 
when glycaemia rises, storing it as glycogen (see Section 2.1). By contrast, when 
blood glucose falls, and other organs require energy, the liver produces glucose by 
glycogenolysis and gluconeogenesis. Therefore, the correct hepatic response to 
insulin and hepatic metabolism are critical for maintaining glycaemia within physi-
ological ranges, and therefore for the proper control of diabetes.
Studies with PASK−/− mice have reported the critical role PASK plays in hepatic 
adaptation to fasting/feeding periods, especially under an HFD [93, 112]. It is 
interesting that PASK expression is regulated in the liver by fasting/feeding, with 
fasting downregulating it [112]. Moreover, Perez-Garcia et al. [113] have found 
that PASK deficiency alters the complex hepatic response to fasting/feeding. The 
expression of the transcription factors and key enzymes that regulate gluconeo-
genesis and mitochondrial fatty acid transport under fasting conditions is altered 
in PASK−/− mice, with lower forkhead box protein O1 (Foxo 1) and carnitine 
palmitoyltransferase 1A (Cpt1a) and higher peroxisome proliferator-activated 
receptor alpha (Ppara). Similarly, PASK deficiency modifies the activity of the 
protein kinase B (AKT) overactivated under fasting and the stability of phospho-
enolpyruvate carboxykinase (PEPCK) [113], while no detectable changes have 
been observed in the maintenance of blood glucose homeostasis during prolonged 
fasting periods [105].
A good example of PASK deficiency effects under feeding involves the changes 
recorded in GCK, which is a critical enzyme in the hepatic function. GCK is an 
enzyme involved in hepatic glucose sensing (see Section 2). This enzyme is acti-
vated by the increase in blood glucose which occurs in feeding periods. It therefore 
adjusts hepatic glucose phosphorylation to blood glucose levels, acting as a glucose 
sensor. The importance of GCK in maintaining glucose homeostasis is evidenced by 
the severe impacts caused by mutations in the GCK gene. The loss of GCK function 
in the human body causes maturity-onset diabetes of the young type 2 (MODY2) 
[114]. By contrast, activating mutations generate persistent hyperinsulinemia [115]. 
Many liver functions are controlled by GCK, which acts together with insulin in the 
maintenance of blood glucose homeostasis [116], and the activation of glycolytic 
and lipogenic gene expression. GCK is also involved in glycogen synthesis and stor-
age in the liver [117]. The enzymatic activity of GCK is controlled by transcriptional 
and posttranscriptional mechanisms. While the transcriptional regulation of the 
GCK gene is basically insulin-dependent [118], the posttranscriptional mechanisms 
of regulation involve interaction with other proteins, highlighting the glucokinase 
regulatory protein (GCKR). GCKR modulates GCK activity when glucose levels 
decline by binding and sequestering it in the nucleus, and thus avoiding its function 
in the cytoplasm [116, 119].
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Studies relating the role of PASK to the GCK function [113] have revealed that 
GCK activity is reduced in PASK−/− mice for two reasons: on the one hand, the 
lower protein expression, and on the other, its mainly nuclear location. It cannot be 
ruled out that the decrease in GCK may be partly due to the blocking of lipogenesis 
that characterizes PASK−/− mice. In addition, the conversion of excess carbohy-
drates into lipids might also be limited by the low levels of acetyl CoA carboxylase 
(ACC) and fatty acid synthase (FAS), although the gene coding to ACC and liver 
pyruvate kinase (LPK) is overexpressed under non-fasted conditions in PASK−/− 
mice. Additionally, glycogen metabolism could also be modified because glycogen 
synthase is a PASK substrate [90].
The hepatic PASK role in the control of hepatic adaptation to fasting/feeding 
becomes more important under an HFD because it dysregulates hepatic metabolic 
responses to fasting and feeding, leading to a non-alcoholic fatty liver, obesity, 
insulin resistance, diabetes, and associated cardiovascular problems. Some stud-
ies have evidenced that PASK−/− mice fed with a HFD resist the development of 
obesity and hepatic steatosis, with improved insulin sensitivity [93, 96, 112]. A 
consequence of an HFD for the liver is that it alters the downregulation of the 
Pask expression produced by fasting, as normally happens in a standard-fat diet 
[112]. Interestingly, PASK−/− mice with an HFD record improved parameters for 
the following: body weight, glucose tolerance, insulin resistance (see Section 6.1.), 
and serum lipid parameters [112]. Some of the PASK effects are due to changes in 
the proteolytic maturation of SREBP1c, others by regulating transcription factors 
and enzymes that play a key role in the hepatic response to fasting/feeding. Thus, 
PASK deficiency compensates for gene expression altered by an HFD. For example, 
it decreases the expression of genes overexpressed in HFD-fed mice (transcription 
factors involved in the regulation of gluconeogenic enzymes, the transport of fatty 
acid into mitochondria, β-oxidation, and de novo lipogenesis). PASK also modi-
fies the expression of the short noncoding RNAs involved in lipid metabolism and 
glucose homeostasis. Such is the case of miR-33a and miR-143, whose expression in 
HFD-fed mice is controlled by PASK. Thus, PASK deficiency improves the hepatic 
adaptation to feeding/fasting, especially under pathogenic situations such as an 
HFD, through a highly regulated molecular mechanism that controls the expression 
and function of the transcription factors, enzymes and miRNAs involved in glucose 
and insulin signaling.
PASK deficiency also improves oxidative metabolism and mitochondrial biogen-
esis [120], increasing the ROS-detoxifying enzymes and the expression of FoxO3a 
and PTEN-induced kinase 1 (PINK1) involved in cell survival and mitophagy, 
respectively. All of these are interesting effects of PASK deficiency for states that 
increase oxidative stress, such as aging, diabetes, and obesity.
In sum, there are several results that highlight PASK’s role in the control of the 
key genes and proteins that lead to hepatic metabolic adaptation to fasting or feed-
ing situations.
Accordingly, PASK has been proposed as one of the possible targets for the 
treatment of the metabolic syndrome.
6. PASK and insulin resistance
The growing interest in the PASK function began with the finding that its defi-
ciency prevents many of the deleterious effects of HFDs [93, 112], with a highlight 
being the insulin resistance that accompanies these diets, and which has been 
widely associated with the development of T2D [121, 122].
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Figure 3. 
Insulin signaling and insulin resistance. Insulin signaling recruit insulin receptor substrates (IRS) activates the 
phosphoinositide 3-kinase (PI3K)/AKT pathway that controls most metabolic effects. In muscle and adipose 
tissue this pathway activates AMP-activated protein kinase (AMPK) promoting glucose transporter type 4 
(GLUT4) expression and translocation to the cell membrane. In the liver this pathway activates glucokinase 
(GCK) and glycogen synthase kinase (GSK) inducing glycogen synthesis and suppresses gluconeogenesis 
inhibiting the expression of phosphoenolpyruvate carboxykinase (PEPCK) and glucose-6-phosphatase 
(G6Pase). Arrow stimulates, T bar red inhibits. Insulin resistance impairs the activation of PI3K/Akt 
pathway. In the skeletal muscle and adipose tissue impairs glucose uptake decreasing GLUT4 expression and 
translocation. In the liver insulin resistance suppresses glycogen synthesis and promotes gluconeogenesis through 
the expression of PEPCK and G6P genes.
The same level of PASK is expressed in pancreatic α and β cells, and it is 
involved in insulin and glucagon secretion [88]. PASK promotes insulin expression 
[108], while PASK deficiency decreases the expression of preproinsulin at high 
glucose concentrations [123]. As for glucagon, PASK regulates its secretion by 
glucose [88].
PASK is also important in the development of pancreatic α and β cells, reflect-
ing its key role in diabetes [89]. Thus, even though PASK deletion does not affect 
glucose-stimulated insulin secretion or insulin levels in response to fasting and 
feedback, it does decrease pancreatic β-cell mass in specific KO animals. By con-
trast, the deletion of PASK in pancreatic α cells improves glucagon secretion both in 
vivo and in vitro. PASK therefore plays a clear role in glucagon secretion and in the 
development of β-cell precursors.
There are two determining factors that promote the onset of T2D, dysfunc-
tions in insulin secretion and peripheral resistance to the action of insulin. We 
cannot speak of a single class of T2D because there is considerable heterogeneity. 
In general, obesity prompts the metabolic syndrome [124], which in addition to 
obesity includes other pathologies such as hypertension, hypertriglyceridemia, 
elevated fasting glucose levels, and dyslipidemia. T2D is associated with insulin 
resistance (Figure 3), and over long periods it can lead to hyperinsulinemia. Finally, 
the pancreas fails and hypoinsulinemia sets in.
Insulin signaling activates the PI3K/AKT pathway that controls most metabolic 
effects (Figure 3) [125]. Insulin stimulates glucose uptake in muscle and adipose tis-
sue, promoting glucose transporter type 4 (GLUT4) expression and translocation to 
the cell membrane [126, 127]. In turn, insulin decreases lipolysis in adipose tissue, 
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reducing the level of circulating free FA [128]. Insulin in the liver induces glycogen 
synthesis and suppresses gluconeogenesis [75].
The loss of sensitivity to insulin, generally called insulin resistance, affects this 
hormone’s main peripheral target organs [125]. Insulin resistance could increase 
the concentration of free FA in the blood [129], decrease glucose uptake in skeletal 
muscle, and stimulate gluconeogenesis, increasing glucose release in the liver, 
thereby contributing to the metabolic syndrome [130, 131]. Abdominal obesity 
releases an excess of free FA, and the associated inflammation may interfere with 
insulin signaling [132].
6.1 Obesity, insulin resistance and PASK
Obesity in humans is defined as a body mass index (BMI = weight/height2) of 
more than 30 kg/m2. There are numerous studies linking fat intake and the onset 
of T2D, but it has not been possible to establish a consensus on the relationship 
between fat intake and obesity. A positive correlation has nonetheless been estab-
lished between fat consumption and the BMI by Nagao et al. [121]. Moreover, the 
effect of consuming animal fats that contain high amounts of saturated fatty acids 
(SFAs) has also been compared with the consumption of fat with monounsaturated 
(MUFA) or polyunsaturated fatty acids (PUFA). PUFA intake is reported to reduce 
the risk of T2D. The variability detected also depends on the genetic factors that 
contribute 40% to the development of T2D [121].
Genetic variability is also considered in studies on the effect of an HFD in mice 
[121, 133]. In sum, a diet containing high amounts of animal or vegetable fat rich in 
saturated or unsaturated FA ω6/ω9 increases body weight and resistance to insulin 
appears, and to compensate there is an increase in insulin levels. These effects are 
not observed when using oils rich in unsaturated FA ω3 [134].
The liver’s key function of maintaining metabolic homeostasis in both fasting 
and a postprandial state makes it one of the main organs affected by an HFD. It 
has been posited that a long-term HFD induces lipid (triglycerides) accumulation 
in hepatocytes as a result of insulin resistance. Nonalcoholic fatty liver disease 
(NAFLD) is the first step toward the onset of a chronic condition. This first step is 
followed by oxidative stress and impairment of the mitochondrial function, which 
triggers associated inflammation, hepatic damage and fibrosis [135, 136].
PASK−/− mice are protected against hepatic steatosis and the insulin resistance 
induced by an HFD [93]. We have reported that a long-term HFD severely alters the 
liver response needed to maintain metabolic homeostasis during fasting and feeding 
periods [112]. Firstly, the hepatic Pask expression is stimulated by feeding [96]. By 
contrast, HFD-fed mice have similar levels of hepatic Pask gene expression under 
fasting and feeding conditions [112]. Our results suggest that this effect might be 
responsible for some of the metabolic changes associated with this diet.
An HFD has a drastic effect on the expression of transcription factors that 
regulate the adaptation to fasting/feeding conditions. For instance, the transcrip-
tion factors (FOXO1, peroxisome proliferator-activated receptor γ coactivator 
1α (PGC1α) and PPARα) stimulated under fasting to promote the expression of 
the gluconeogenic enzymes (PEPCK and glucose 6-phosphatase (G6Pase)) and 
the genes that support fatty acid transport into mitochondria and β-oxidation are 
significantly overstimulated in HFD-fed mice. However, PASK deficiency blocks or 
diminishes the expression of all these genes under an HFD.
Similarly, the adaptation to a postprandial state is regulated by glucose and 
insulin through the expression of transcriptional factors (carbohydrate-responsive 
element-binding protein (CHREBP), liver X receptor alpha (LXRα) and SREBP1) 
[137, 138]. They promote the expression of lipogenic genes (Acc1, Fas and 
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stearoyl-CoA desaturase-1 (Scd1)), stimulating the conversion of excess carbohy-
drates into FA and triglycerides. An HFD also overexpresses both Lxrα and peroxi-
some proliferator-activated receptor gamma (Pparγ) but this effect is diminished 
in PASK−/− mice [112]. The overexpression of Lxrα [139] and Pparγ [140, 141] has 
previously been associated with liver steatosis in human and mouse models of 
obesity and diabetes.
The effects of an HFD cause multiple changes in transcription factors and the 
key enzymes of the main hepatic metabolic pathways that allow metabolic adapta-
tion. Genes promoting de novo lipogenesis that are expressed only under feeding 
conditions with a standard diet can also be overexpressed under fasting conditions 
with an HFD, which induces the overexpression of transcription factors and meta-
bolic enzyme genes controlling de novo lipogenesis (Chrebp, Lxrα, Srebp1c, Acc1 and 
Scd1) under a fasted state [112].
PASK deficiency eliminates many harmful effects that HFDs cause in the liver 
(Figure 3), also decreasing the lipid depots that over time can develop hepatic 
steatosis. Thus PASK−/− mice under an HFD have lower blood glucose levels, 
improve their sensitivity to the action of insulin, preventing the appearance of 
insulin resistance, which in turn is correlated with smaller increases in body weight 
and improved lipid profile [112]. PASK pharmacologic inhibition likewise confirms 
its key role for restoring insulin sensitivity, and for reducing hepatic fat content and 
the fibrosis caused by an HFD [98].
6.2 Aging, insulin resistance and PASK
The risk of T2D increases in aging due to the many imbalances that character-
ize this stage of life, which are often associated with overweight, impaired glucose 
metabolism, hypertension and dyslipidemia [142].
The aging process is characterized metabolically by the following: the develop-
ment of insulin resistance (Figure 3), changes in body composition and mitochon-
drial dysfunction. In addition, hyperinsulinemia and glucose intolerance develop 
during aging [143, 144]. There are numerous metabolic changes in peripheral 
tissues that affect the uncontrolled gluconeogenesis of the liver, accompanied by an 
increase in lipogenesis in adipose tissue, and by defects in glycogen synthesis and 
glucose uptake in skeletal muscle [144]. Glucose metabolic dysfunction is closely 
correlated with oxidative stress, as occurs in diabetic or obese patients [145, 146].
Aging is normally accompanied by an increase in visceral fat, which is one of 
the main contributors to insulin resistance and the development of T2D. Likewise, 
it leads to an increase in proinflammatory cytokines, which interfere with insulin 
activity [144].
Another consequence of aging is the progressive loss of mitochondrial function 
in various tissues such as the liver or skeletal muscle. Thus, certain studies affirm 
that there is an association in aging between insulin resistance and glucose intoler-
ance, together with a reduction in oxidative activity and mitochondrial ATP synthe-
sis [144]. With aging, the liver undergoes molecular changes such as an increased 
inflammatory response, dysregulation of the genetic expression of antioxidant 
enzymes, and mitochondrial dysfunction, significantly altering redox homeostasis. 
It is also accompanied by the liver’s reduced capacity for regeneration, which greatly 
affects liver function [147].
The nutrient sensing mechanisms needed to detect and respond to variations 
in their levels are dysregulated by aging [148]. So both nutrient sensor pathways, 
AMPK and mTORC1, are involved in a lifespan [149]. PASK senses intracellular 
oxygen, redox state and various metabolites [100]. Additionally, PASK regulates 
both AMPK and mTORC1 pathways [104, 105]. The aging process at cellular level is 
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regulated by insulin/IGF signaling and both AMPK and mTORC1 pathways, which 
are in turn regulated by nutrient levels, whose signals converge on several targets: 
FOXO, nuclear factor: erythroid-derived 2-like 2 (NRF2), tumor protein p53, and 
sirtuins (SIRT) in order to control metabolic homeostasis, oxidative stress, and 
quality cellular housekeeping [150].
PASK−/− mice may avoid several of the deleterious defects induced by the aging 
process [151]. Aged PASK−/− mice maintain both low blood glucose values and insu-
lin concentrations similar to young WT mice. They do not develop glucose intoler-
ance or insulin resistance, as confirmed by a normal HOMA-IR index. These effects 
correlate with a high expression of the longevity gene FoxO3a and the transcription 
factor NRF2, as the main regulator of the redox balance [151]. Signaling through 
the system NRF2/KEAP1: kelch-like ECH-associated protein 1 regulates the tran-
scription of enzymes that protect cells against oxidative stress [152]. An elevated 
expression of glutamate-cysteine ligase modifier subunit (GCLm) and heme 
oxygenase-1 (HO1) have been found in aged PASK−/− mice under fasted condi-
tions. The efficiency of this redox system decreases in step with aging in WT mice, 
significantly diminishing the antioxidant response [153]. Likewise, PASK deficiency 
prevents the drastically age-related decrease in the expression of several antioxidant 
enzymes under basal conditions, such as catalase (CAT) and glutathione peroxidase 
(GPx) [151].
In relation to the maintenance of the mitochondrial function and energy homeo-
stasis, we have confirmed that the expression of the several transcription factors 
and nuclear receptors needed to maintain mitochondrial biogenesis (Ppargc1a, 
Sirt1 and Nrf2) are affected in fasted aged WT mice [151] in accordance with the 
previous literature that relates aging to a decrease in cellular energy input [154], 
an increase in oxidative stress [155], and the mitochondrial dysfunction of cellular 
redox homeostasis [156, 157]. However, the expression of Nrf2, Ppargc1a, Pparγ and 
Sirt1 increases under fasting in aged PASK−/− mice. This means they maintain lower 
levels of ROS/RNS, while aged WT mice record a lower expression of antioxidant 
enzymes and increased levels of ROS/RNS [151].
We might therefore contend that some of the dysfunctions produced during 
aging in PASK−/− mice could be related to hormetic responses. Slight toxic effects 
can generate beneficial actions that compensate for the initial damage and even 
improve cellular health [158]. Aging decreases Pask expression in the liver of WT 
mice perhaps as a compensatory mechanism. PASK−/− mice maintain the same blood 
glucose values as young WT mice, and do not develop insulin resistance.
7. Conclusions
PASK function could be critical for preserving the nutrient effect on hypotha-
lamic AMPK and mTORC1/S6K1 pathways and maintain the regulatory role of 
GLP1/exendin-4 in food intake.
PASK regulates the hepatic glucose sensor GCK and AKT, an insulin signal-
ing intermediators, and glucose and lipidic metabolism through the regulation of 
the key genes and proteins required during hepatic fasting/feeding adaptation. 
Moreover, PASK deficiency improves mitochondrial biogenesis and antioxidant 
mechanisms.
HFDs alter the adaptive response of Pask gene expression to fasting/feeding. 
PASK deficiency eliminates many of the harmful effects HFDs have on the liver, 
thereby decreasing the lipid depots. PASK deficiency decreases the expression of 
several transcription factors stimulated under fasted conditions to promote the 
expression of the gluconeogenic enzymes and those promoting the expression of 
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lipogenic genes after feeding that are significantly overstimulated in wild type 
HFD-fed mice.
PASK deficiency avoids insulin resistance and glucose intolerance during aging, 
preventing an age-related decrease in the expression of several antioxidant enzymes 
and improving mitochondrial function.
All these actions make PASK a significant pharmacological target for diseases, 
such as obesity and diabetes, and for preventing some of the more harmful effects 
of aging.
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